Arm C genes, in contrast, were enriched for the activation associated markers CD69, JUNB, and XCL143; cytoskeletal and proliferation markers DDIT1 (REDD1), CAPG, and LDLRAD4; cytokines CCL4 and CCL4L2; the ECM glycoprotein SPARC (osteonectin); and IL7R. Overall these data suggest that addition of a CD137 agonist to GVAX and anti-PD1 therapy induces cytoskeletal and ECM alterations, reduces exhaustion markers, and enhances tumor-infiltrating CD8+ T cell activation and proliferation. This evidence concerns the gene CD69 and neoplasm.